The Multiple Myeloma Channel is supported with funding from Sanofi (Gold) and Legend Biotech (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
EHA 2026 | The potential of using WGS of CTCs to monitor for genetic alterations in multiple myeloma
Bruno Paiva, PhD, University of Navarra, Pamplona, Spain, discusses the potential of using whole genome sequencing (WGS) of circulating tumor cells (CTCs) as a minimally invasive method for monitoring genetic alterations in patients with multiple myeloma (MM). Dr Paiva highlights that the genomic architecture of CTCs is almost identical to that of myeloma cells in the bone marrow, with high concordance with gold-standard assays, enabling more frequent longitudinal tracking of genetic alterations from blood samples. This interview took place at the 31st Congress of the European Hematology Association (EHA) in Stockholm, Sweden.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
